CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM089545
035-os BibID:(WOS)000600601200003 (Scopus)85097310520
Első szerző:Burmester, Gerd R.
Cím:Evolving the comprehensive management of rheumatoid arthritis : identification of unmet needs and development of practical and educational tools / G. R. Burmester, J. M. Álvaro-Gracia, N. Betteridge, J. Calvo Alén, B. Combe, P. Durez, B. Fautrel, R. J. O. Ferreira, C. Gabay, A. Iagnocco, C. Montecucco, M. štergaard, S. Ramiro, A. Rubbert-Roth, T. Stamm, Z. Szekanecz, P. C. Taylor, M. van de Laar
Dátum:2020
ISSN:0392-856X
Megjegyzések:Objectives: Despite availability of efficacious treatments, unmet needs still exist, preventing optimal and comprehensive management of rheumatoid arthritis (RA). Evolving the management of RA (eRA) is a European-wide educational initiative aiming to support improved patient care through practical and educational tools addressing specific unmet needs. Methods: A multidisciplinary Steering Committee (17 members, 12 countries) identified unmet needs within the management of RA and prioritised those with the greatest impact on patient outcomes. Practical educational tools addressing priority needs were then developed for dissemination and implementation by the rheumatology community across Europe. Results: Five areas of priority need were identified: increasing early recognition of RA and treatment initiation; treating RA to target; optimal, holistic approach to selection of treatment strategy, including shared decision-making; improving identification and management of comorbidities; and non-pharmacological patient management. A suite of 14 eRA tools included educational slides, best-practice guidance, self?assessment questionnaires, clinical checklists, a multidisciplinary team training exercise, an interactive patient infographic, and case scenarios. By April 2020, rheumatology professionals in 17 countries had been actively engaged in the eRA programme; in 11 countries, eRA tools were selected by national leaders in rheumatology and translated for local dissemination. A web platform, with country-specific pages, was developed to support access to the translated tools (https://www.evolvingthemanagementofra.com/). Conclusions: The eRA programme supports comprehensive management of RA across Europe through development and dissemination of practical educational tools. The eRA tools address priority needs and are available free of charge to the rheumatology community.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Rheumatoid arthritis
medical education
delivery of health care
rheumatology
patient care team
Megjelenés:Clinical And Experimental Rheumatology. - 38 (2020), p. 1056-1067. -
További szerzők:Álvaro-Gracia, Jose María Betteridge, Neil Calvo Alén, Jaime Combe, Bernard Durez, Patrick Fautrel, Bruno Ferreira, Ricardo J. O. Gabay, Cem Iagnocco, Annamaria Montecucco, Carlo Maurizio štergaard, Mikkel Ramiro, Sofia Rubbert-Roth, Andrea Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Taylor, Peter C. van de Laar, Mart
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM067427
035-os BibID:(WoS)000401138800008 (Scopus)85007256365
Első szerző:Combe, Bernard
Cím:2016 update of the EULAR recommendations for the management of early arthritis / Bernard Combe, Robert Landewe, Claire I. Daien, Charlotte Hua, Daniel Aletaha, Jose María Álvaro-Gracia, Margôt Bakkers, Nina Brodin, Gerd R. Burmester, Catalin Codreanu, Richard Conway, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Joao Fonseca, Karim Raza, Lucía Silva-Fernández, Josef S. Smolen, Diana Skingle, Zoltan Szekanecz, Tore K. Kvien, Annette van der Helm-van Mil, Ronald van Vollenhoven
Dátum:2017
ISSN:0003-4967
Megjegyzések:Objectives Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.Methods In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of ♭management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process.Results The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research.Conclusions These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 6 (2017), p. 948-959. -
További szerzők:Landewé, Robert Daien, Claire I. Hua, Charlotte Aletaha, Daniel Álvaro-Gracia, Jose María Bakkers, Margôt Brodin, Nina Burmester, Gerd R. Codreanu, Catalin Conway, Richard Dougados, Maxime Emery, Paul Ferraccioli, Gianfranco Fonseca, João Raza, Karim Silva-Fernández, Lucía Smolen, Josef S. Skingle, Diana Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kvien, Tore K. van der Helm-van Mil, Annette van Vollenhoven, Ronald
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM081587
Első szerző:Najm, Aurélie
Cím:EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases / Aurélie Najm, Elena Nikiphorou, Marie Kostine, Christophe Richez, John D. Pauling, Axel Finckh, Valentin Ritschl, Yeliz Prior, Petra Balázová, Simon Stones, Zoltan Szekanecz, Annamaria Iagnocco, Sofia Ramiro, Francisca Sivera, Maxime Dougados, Loreto Carmona, Gerd Burmester, Dieter Wiek, Laure Gossec, Francis Berenbaum
Dátum:2019
Megjegyzések:Background Mobile health applications (apps) are available to enable people with rheumatic and musculoskeletal diseases (RMDs) to better self-manage their health. However, guidance on the development and evaluation of such apps is lacking. Objectives The objective of this EULAR task force was to establish points to consider (PtC) for the development, evaluation and implementation of apps for self-management of RMDs. Methods A systematic literature review of app content and development strategies was conducted, followed by patient focus group and an online survey. Based on this information and along with task force expert opinion, PtC were formulated in a face-to-face meeting by a multidisciplinary task force panel of experts, including two patient research partners. The level of agreement among the panel in regard to each PtC was established by anonymous online voting. Results Three overarching principles and 10 PtC were formulated. Three PtC are related to patient safety, considered as a critical issue by the panel. Three are related to relevance of the content and functionalities. The requirement for transparency around app development and funding sources, along with involvement of relevant health professionals, were also raised. Ease of app access across ages and abilities was highlighted, in addition to considering the cost benefit of apps from the outset. The level of agreement was from 8.8 to 9.9 out of 10. Conclusion These EULAR PtC provide guidance on important aspects that should be considered for the development, evaluation and implementation of existing and new apps.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Rheumatic and Musculoskeletal Diseases. - 5 (2019), p. 1-7. -
További szerzők:Nikiphorou, Elena (reumatológus) Kostine, Marie Richez, Christophe Pauling, John D. Finckh, Axel Ritschl, Valentin Prior, Yeliz Balázová, Petra Stones, Simon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Iagnocco, Annamaria Ramiro, Sofia Sivera, Francisca Dougados, Maxime Carmona, Loreto Burmester, Gerd R. Wiek, Dieter Gossec, Laure Berenbaum, Francis
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM125867
035-os BibID:(WoS)001384841700001 (Scopus)85216077915
Első szerző:Sebbag, Eden
Cím:Systematic literature review and meta-analysis informing the EULAR Points to Consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer / Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Maya H. Buch, Gerd R. Burmester, Helena M. Canhão, Katerina Chatzidionysiou, Jeffrey R. Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K. Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Nathanaël Sedmak, Lucia Silva-Fernandez, Zoltan Szekanecz, Kim Lauper, Axel Finckh, Jacques-Eric Gottenberg
Dátum:2025
ISSN:0003-4967
Megjegyzések:Background Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer. Objectives To perform a systematic literature review to inform a Task Force formulating EULAR Points to Consider on the initiation of targeted therapies in patients with IA and a history of cancer. Methods Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian. We included studies reporting a relative risk measure of patients with a history of cancer initiating a targeted therapy or a conventional synthetic disease-modifying antirheumatic drug (csDMARD), regardless of the time since diagnosis of cancer. All relevant studies included in PubMed or Embase up to 15 July 2022 were included. Two reviewers independently performed standardised article selection, data extraction, synthesis and risk of bias assessment. Results 14 published articles and one ACR abstract fulfilled the inclusion criteria. All studies were high quality observational studies, representing a median follow-up from treatment initiation of 4.52 years among 4428 patients and 15 062 patient-years of follow-up for new or recurrent cancer. All patients had a history of cancer, most frequently solid cancer, most frequently receiving treatment for rheumatoid arthritis and most frequently treated with tumour necrosis factor-alpha inhibitors. Across these studies, the overall HR of cancer recurrence was 0.92 (95% CI 0.74 to 1.15) for patients receiving a targeted therapy versus a csDMARD. Conclusion Overall, the targeted therapies and clinical contexts covered by the included studies were not associated with an increased risk of cancer recurrence as compared with csDMARDs
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 84 : 4 (2025), p. 643-652. -
További szerzők:Molina-Collada, Juan Ndoye, Ramatoulaye Aletaha, Daniel Askling, Johan Gente, Karolina Bertheussen, Heidi Bitoun, Samuel Bolek, Ertugrul Cagri Buch, Maya H. Burmester, Gerd R. Canhão, Helena M. Chatzidionysiou, Katerina Curtis, Jeffrey R. Danlos, Francois-Xavier Guimarães, Vera Hetland, Merete Lund Iannone, Florenzo Kostine, Marie Kragstrup, Tue Wenzel Kvien, Tore K. Regierer, Anne Constanze Schulze-Koops, Hendrik Sedmak, Nathanaël Silva-Fernández, Lucía Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Lauper, Kim Finckh, Axel Gottenberg, Jacques-Eric
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM125841
035-os BibID:(Scopus)85215863302 (WoS)001384841300001
Első szerző:Sebbag, Eden
Cím:2024 EULAR Points to Consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer / Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Gerd R. Burmester, Helena M. Canhão, Katerina Chatzidionysiou, Jeffrey R. Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K. Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Lucia Silva-Fernandez, Zoltan Szekanecz, Maya H. Buch, Axel Finckh, Jacques-Eric Gottenberg
Dátum:2024
ISSN:0003-4967
Megjegyzések:Background Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice. Objectives To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.Methods Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC. Results The group formulated five OPs; seven PTC were formulated concerning the initiation of targeted therapies in patients with active IA and a previous malignancy in remission and one PTC concerning patients with active IA who were not in cancer remission. Major themes included (a) the need to assess the individualised risk of cancer recurrence based on the characteristics of the patient, cancer and the underlying disease; (b) the importance of engaging with specialists caring for cancer and defining treatment based on a shared decision between the patient and the rheumatologist; (c) the value of initiating without delay an appropriate targeted therapy for the treatment of the IA in patients in remission of their cancer; (d) the proposal to use Janus kinase inhibitors and abatacept with caution and in the absence of therapeutic alternatives, based on the absence of any data concerning their use in the context of previous malignancy. Conclusion The 2023 EULAR Points to Consider provide guidance on the management of targeted therapies in patients with IA and a previous malignancy.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 84 : 3 (2024), p. 388-397. -
További szerzők:Lauper, Kim Molina-Collada, Juan Aletaha, Daniel Askling, Johan Gente, Karolina Bertheussen, Heidi Bitoun, Samuel Bolek, Ertugrul Cagri Burmester, Gerd R. Canhão, Helena M. Chatzidionysiou, Katerina Curtis, Jeffrey R. Danlos, Francois-Xavier Guimarães, Vera Hetland, Merete Lund Iannone, Florenzo Kostine, Marie Kragstrup, Tue Wenzel Kvien, Tore K. Regierer, Anne Constanze Schulze-Koops, Hendrik Silva-Fernández, Lucía Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buch, Maya H. Finckh, Axel Gottenberg, Jacques-Eric
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.